Trials / Completed
CompletedNCT03920228
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Palvella Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PTX-022 | PTX-022 QTORIN |
| DRUG | Placebo | Placebo topical |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2020-09-19
- Completion
- 2020-10-19
- First posted
- 2019-04-18
- Last updated
- 2024-08-29
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03920228. Inclusion in this directory is not an endorsement.